| brand name for cimetidine | Tagamet |
| brand name for omeprazole | prilosec |
| brand name for metoclopramide | reglan |
| brand name for loperamide | immodium |
| brand name for docusate | colace |
| generic name for tagamet | cimetidine |
| generic name for prilosec | omeprazole |
| generic name for immodium | ioperamide |
| generic name for colace | docusate |
| cimetidine (Tagamet) classification | histamine h2 antagonist |
| omeprazole (Prilosec) classification | proton pump inhibitor |
| metoclopramide (reglan) classification | GI stimulant |
| ioperamide (immodium) classification | antidiarrheal |
| docusate (colace) classification | stool softener/ surfactant |
| milk of magnesia classification | antacid/ laxative |
| promethazine classification | antiemetic |
| cimetidine (Tagamet) nursing considerations | - be alert to onset of confusional states
- monitor I&O ratio and pattern |
| omeprazole (Prilosec) nursing considerations | - monitor urinalysis for hematuria and proteinuria |
| metoclopramide (reglan) nursing considerations | - periodic serum electrolyte
- monitor for possible hypernatremia and hypokalemia , especially if patient has CHF or cirrhosis |
| ioperamide (immodium) nursing considerations | - monitor therapeutic effectiveness
- monitor fluid and electrolyte balance |
| docusate (colace) nursing considerations | - withhold drug if diarrhea develops and notify physician
- therapeutic effectiveness usually apparent 1-3 days after first dose |
| milk of magnesia nursing considerations | - evaluate patients continued need for drug
- monitor serum magnesium with signs of hypermagnesemia such as bradycardia, especially with frequent use or any degree of renal impairment |
| promethazine nursing considerations | - supervise ambulation
- monitor respiratory function in patients with respiratory problems, particularly in children |
